Could a common heart drug boost ovarian cancer treatment?
NCT ID NCT07125391
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding propranolol, a widely used beta-blocker, to standard chemotherapy before surgery can improve outcomes for women with advanced high-grade serous ovarian cancer. Participants receive propranolol pills alongside paclitaxel and carboplatin, followed by surgery to remove tumors. The study aims to see if this combination leads to better tumor shrinkage and more complete surgical removal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
propranolol hydrochloride
What this could lead to
If successful, adding propranolol to standard chemotherapy could improve surgical outcomes and extend survival for women with advanced ovarian cancer.
What could go wrong
This is a phase 2 trial with 136 participants, so results are preliminary. Propranolol may cause side effects like low blood pressure or fatigue, and the benefit seen in earlier studies may not hold up.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Cancer Hospitail
RECRUITINGHefei, Anhui, 230001, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••